The Yield Lab Europe
The Yield Lab Europe is one of the largest early stage VC investors in early stage Agrifood tech companies in Europe in the pre-seed to Series A range. As an impact investor, it invests in technologies that improve the sustainability of the agrifood industry. It also provides access to the Yield Lab global network of experts, corporates and investors all around the world to help startup companies scale and commercialise internationally.
Rubio Impact Ventures
Rubio Impact Ventures is a leading impact venture fund based in the Netherlands with € 150 million AUM. Rubio invests in world-changing entrepreneurs who unite powerful positive impact with a scalable commercial business; the future-proof approach to successful business. Rubio offers its investments a winning blend of capital, expertise and network access to help them accelerate to the next level. Want to find out more?
Founded 2017, Cavallo Ventures is the VC arm of Wilbur-Ellis, we enable innovative technology across all business divisions and markets of Wilbur-Ellis globally. As early investors and active board members, we employ a hands-on approach to building companies and are often directly involved in setting company strategy, recruiting key executives and raising additional capital. Much more than simply a financial resource, we aim to deliver value through active collaboration with our strategic partners and network.
Scottish Enterprise is Scotland’s national economic development agency.
We’re committed to growing the Scottish economy for the benefit of all, helping create more quality jobs and a brighter future for the whole of Scotland, with the transition to net zero at the heart of our focus.
We work with partners in the public and private sector to identify and maximise opportunities to deliver a significant, lasting effect on the economy.
We support thousands of companies across the country, helping catalyse the changes in our economy that will have a long-term positive impact on Scotland’s business competitiveness around the world. In doing so, we’re creating significantly more, better jobs, helping people fulfil their potential.
Scottish Enterprise’s Growth Investments Team invests in and supports early-stage companies and the investment market, including inward investment opportunities to ensure both early stage and established businesses with growth and export potential have adequate access to growth capital.
SIS Ventures, a wholly-owned subsidiary of Social Investment Scotland (SIS), provides the tools and mission-aligned investment required to help early-stage businesses grow and deliver impact at scale. In return for investment, SIS Ventures seeks a mission lock – where the social and/or environmental mission of the organisation is locked into the Articles of Association and cannot be changed without consent. Launched in 2018 and authorised by the Financial Conduct Authority, SIS Ventures has already raised and deployed its first c.£1.3m Impact First EIS fundraise. It is currently deploying £5m Scottish Government funding into follow-on rounds of existing portfolio investee businesses as well as into new impactful business opportunities. [SIS Ventures is a signatory to the Operating Principles of Impact Management which provide a global framework for investors to ensure that impact considerations are integrated throughout an investment lifecycle. Targets for investment include businesses which are committed to progressing the diversity and inclusion agenda and those whose products or services progress the United Nations Sustainable Development Goals.
UKi2S is early stage seed to series A fund building companies addressing notable global challenges. Backing complex and high risk science and engineering with the potential for significant impact, the fund is backed by the Department for Business, Energy and Industrial Strategy and the Fund’s partners are 9 publicly funded research bodies, including STFC, BBSRC, NERC and Dstl. The fund holds investments in some of the UK’s most innovative companies, in areas as diverse as novel antibiotics, research into Alzheimer’s disease, “green” chemicals and airport security.